Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer By Ogkologos - November 24, 2025 311 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LUNAR study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Targeted Drug Trio Improves Survival in Colorectal Cancer with BRAF Mutations November 13, 2019 Increased Risk of Cancer in Early Life Among Individuals with Autism... April 28, 2022 New Research in Treating Non-Hodgkin Lymphoma and Predicting the Risk of... January 26, 2023 Prognostic Significance of Lynch-like versus Sporadic MSI-H Endometrial Cancer Treated With... July 20, 2021 Load more HOT NEWS Diagnosed Alone Savolitinib Shows Promise in Pulmonary Sarcomatoid Carcinoma and Other METex14-positive NSCLC... How I Rebuilt My Self-Image After a Laryngectomy: A Cancer Survivor’s... European Lung Cancer Congress 2025, Paris, France, 26-29 March 2025
